Therefore, clinical strategies involving L-carnitine for HCC may include targeting key acting enzymes (e.g., GSTK1, CPT1A, and CPT2), combining L-carnitine with other drugs (e.g., Mdivi-1 and mitophagy inhibitors), and implementing nutritional interventions. Here, CPT1A is linked to hepatocellular carcinoma.